Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

Asia Pac IPO & Placement Research, China biotech

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Viva Biotech Holdings / Equity Capital Markets

<p>Viva Biotechnology, a China-based drug discovery company, is seeking to raise USD 200m to list on the Hong Kong Stock Exchange. In this insight, we cover the following topics:</p>
<ul class="">
<li>Services provided by Viva. </li>
<li>Revenue model of the company.</li>
<li>The CRO market.</li>
<li>The company's history and shareholders.</li>
<li>Our initial thoughts on valuation.</li>
</ul>
<div>
<h2> Our previous coverage on CRO Listings</h2>
</div>
<ul>
<li><a href="https://www.smartkarma.com/insights/wuxi-apptec-ipo-this-a-h-listing-will-be-different" target="_blank">WuXi Apptec (药明康德) IPO: This A+H Listing Will Be Different</a></li>
<li><a href="https://www.smartkarma.com/insights/frontage-holding-ipo-more-disclosure-needed-to-understand-moat-and-growth-prospect" target="_blank">Frontage Holding (方达控股) IPO: More Disclosure Needed to Understand Moat and Growth Prospect</a></li>
</ul>

Viva Biotechnology, a China-based drug discovery company, is seeking to raise USD 200m to list on the Hong Kong Stock Exchange. In this insight, we cover the following topics:

Services provided by Viva. 
Revenue model of the company.
The CRO market.
The company's history and shareholders.
Our initial thoughts on valuation.


 Our previous coverage on CRO Listings


WuXi Apptec (药明康德) IPO: This A+H Listing Will Be Different
Frontage Holding (方达控股) IPO: More Disclosure Needed to Understand Moat and Growth Prospect


Viva Biotech (维亚生物) IPO: When CRO Becomes Early Stage Biotech Investor

Frontage Holdings / Equity Capital Markets

<p>Frontage Holding, a contract research organization subsidiary of A-share listed <a href="https://www.smartkarma.com/entities/397" target="_blank" data-smartkarma-citation="entities:397:1">Hangzhou Tigermed Consulting (300347 CH)</a>, filed to list on the Hong Kong Stock Exchange. </p>
<p>In this insight, we will look at the following topics:</p>
<ul>
<li>Services provided by Frontage. </li>
<li>Revenue models of the company.</li>
<li>The CRO market.</li>
<li>The company's history and shareholders.</li>
<li>Our initial thought on valuation.</li>
</ul>

Frontage Holding, a contract research organization subsidiary of A-share listed Hangzhou Tigermed Consulting (300347 CH), filed to list on the Hong Kong Stock Exchange. 
In this insight, we will look at the following topics:

Services provided by Frontage. 
Revenue models of the company.
The CRO market.
The company's history and shareholders.
Our initial thought on valuation.


Frontage Holding (方达控股) IPO: More Disclosure Needed to Understand Moat and Growth Prospect

China

Frontage Holdings Corporation operates as a biotechnology company. The Company offers clinical trials, bioequivalence studies, medical writing, and agrochemical services. Frontage Holdings serves customers in Hong Kong.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Frontage Holdings (1521 HK)

Viva Biotech (维亚生物) IPO: When CRO Becomes Early Stage Biotech Investor

Viva Biotechnology, a China-based drug discovery company, is seeking to raise USD 200m to list on the Hong Kong Stock Exchange. In this insight, we...

Ke Yan, CFA, FRM

Frontage Holding (方达控股) IPO: More Disclosure Needed to Understand Moat and Growth Prospect

Frontage Holding, a contract research organization subsidiary of A-share listed Hangzhou Tigermed Consulting (300347 CH), filed to list on the Hong...

Ke Yan, CFA, FRM

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)